February 13, 2023
Sorrento Therapeutics, Inc.
Case Number:
4:23-bk-90085
Court:
Nature of Suit:
Firms
- ASK LLP
- Baker Botts
- Bressler Amery
- Buchalter APC
- Chapman & Cutler
- Clark Hill
- Coats Rose
- Cowles & Thompson
- Davis Graham
- DLA Piper
- Doyle Restrepo
- Duane Morris
- Finch Thornton
- Franklin Soto Leeds
- Gibbs Giden
- Glenn Agre
- Gray Reed
- Greenberg Traurig
- Harvest LLP
- Husch Blackwell
- Jackson Walker LLP
- Kane Russell
- Katten Muchin
- Kean Miller
- Locke Lord
- Martin P. Eramo APC
- Maynard Nexsen
- McGuireWoods
- Milbank LLP
- Miller Nash LLP
- Munsch Hardt
- Norton Rose
- Paul Hastings
- Pillsbury Winthrop
- Porter Hedges
- Quinn Emanuel
- Reed Smith
- Ross Smith & Binford
- Shook Hardy
- Sidley Austin
- Thompson Coburn
- Tran Singh
- Troutman Pepper
- Tucker Arensberg
- Vinson & Elkins
- Warshaw Burstein
- WilmerHale
Companies
- ABN AMRO Bank NV
- Apex Clearing Corporation
- Bank of America Corp.
- Barclays PLC
- BMO Capital Markets Corp.
- BMO Harris Bank NA
- Cetera Financial Institutions
- Charles River Laboratories International Inc.
- Edward D. Jones & Co. LP
- Emas Pharma Ltd.
- FMR LLC
- Fortis Advisors LLC
- FTI Consulting Inc.
- HSBC Holdings PLC
- Interactive Brokers Group Inc.
- JPMorgan Chase & Co.
- Kilroy Realty Corporation
- LPL Financial Holdings Inc.
- Mayo Foundation for Medical Education and Research
- Morgan Stanley
- New England Biolabs Inc.
- Oracle Corp.
- PCI Pharma Services
- Pershing Group LLC
- Phillip Capital Inc.
- Prospect Medical Holdings Inc.
- Protiviti Inc.
- Raymond James Financial Inc.
- Robert Half Inc.
- Sorrento Therapeutics Inc.
- Stretto Inc.
- The Bank of New York Mellon Corp.
- The Charles Schwab Corp.
- The Goldman Sachs Group Inc.
- The Scripps Research Institute
- TR Capital Management LLC
- UBS Group AG
- Wedbush Securities Inc.
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
March 26, 2024
Sorrento Gets Green Light To Delay $21M Ch. 11 Sale
Drug developer Sorrento Therapeutics can push the close of its $20.9 million asset sale from Thursday to April 1, a Texas bankruptcy judge ruled Tuesday, after attorneys for the debtor said they reached new terms for the deal that will help fund the company as it winds down under its Chapter 11 plan.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login